Recursion Pharmaceuticals Inc (NASDAQ: RXRX) on Monday, plunged -7.37% from the previous trading day, before settling in for the closing price of $8.41. Within the past 52 weeks, RXRX’s price has moved between $4.54 and $16.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 132.77%. The company achieved an average annual earnings per share of -9.14%. With a float of $146.68 million, this company’s outstanding shares have now reached $226.26 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Recursion Pharmaceuticals Inc is 32.04%, while institutional ownership is 77.32%. The most recent insider transaction that took place on Apr 04 ’24, was worth 360,800. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $9.02, taking the stock ownership to the 938,524 shares. Before that another transaction happened on Apr 04 ’24, when Company’s Chief Executive Officer sold 25,000 for $9.02, making the entire transaction worth $225,500. This insider now owns 0 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 7.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Recursion Pharmaceuticals Inc (RXRX) is currently performing well based on its current performance indicators. A quick ratio of 4.70 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.86 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Compared to the last year’s volume of 6.76 million, its volume of 3.61 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 14.31%. Additionally, its Average True Range was 0.72.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 15.69%, which indicates a significant increase from 0.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.80% in the past 14 days, which was lower than the 95.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.81, while its 200-day Moving Average is $9.34. Nevertheless, the first resistance level for the watch stands at $8.24 in the near term. At $8.69, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.93. If the price goes on to break the first support level at $7.55, it is likely to go to the next support level at $7.32. Should the price break the second support level, the third support level stands at $6.87.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
Market capitalization of the company is 1.68 billion based on 234,653K outstanding shares. Right now, sales total 44,580 K and income totals -328,070 K. The company made 10,890 K in profit during its latest quarter, and -93,000 K in sales during its previous quarter.
